Status:
RECRUITING
Ultrasound Evaluation of Hematoma Risk After Needle EMG in Patient on DOAC Therapy
Lead Sponsor:
Masaryk University
Collaborating Sponsors:
University Hospital Brno
Conditions:
Direct Acting Anticoagulant Adverse Reaction
Needle Injury
Eligibility:
All Genders
Brief Summary
Approximately 30 minutes after needle EMG, patients who are taking direct oral anticoagulants (DOACs) will undergo an ultrasound examination to evaluate for the presence of possible intramuscular hema...
Eligibility Criteria
Inclusion
- Subjects must understand the nature of the study and must provide signed and dated written informed consent prior to conducting any study-related procedures
- Willing and able to comply with all protocol procedures
- subjects confirmed the daily (and recent) intake od direct anticoagulants in strandard dosing.
- no other antitrombotic drug therapy (e.g. acetylsalicyl acid, clopidogrel, ticagralol, low molecular weight heparin or second direct anticoagulant) is taken.
Exclusion
- Any clinically significant medical or psychiatric condition or medical history that, in the opinion of the investigator, would interfere with the subject's ability to participate in the study or increase the risk of participation for that subject
- other antitrombotic drug therapy (e.g. acetylsalicyl acid, clopidogrel, ticagralol, low molecular weight heparin or second direct anticoagulant) is recently taken.
Key Trial Info
Start Date :
September 1 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2026
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT07166302
Start Date
September 1 2025
End Date
December 31 2026
Last Update
September 10 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital Brno
Brno, Czech Republic, Czechia, 62500
2
University hospital Brno
Brno, Czech Republic, Czechia, 62500